Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Its subscription-plus-prescription model applies savings automatically, and third-party codes often expire or do nothing
The FDA cleared orforglipron for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, based on the ATTAIN clinical program which showed placebo-adjusted weight loss of 7.5% to 11.2% in non-diabetics (ATTAIN-1) and 5.1% to 9.6% in diabetics at different doses, along with the expected glycaemic benefits (ATTAIN-2)
Information presented here is for educational purposes only and is not a substitute for consultation with a qualified healthcare provider
Information Type Research Article Information British Journal of Nutrition , Volume 128 , Issue 2 , 28 July 2022 , pp
US$ 27.88
US$ 27.54
US$ 27.85
